Metabolic liver health: how to assess risk, catch dysfunction early, and more (AMA 88 sneak peek)

Episode Overview

• In this preview of Ask Me Anything (AMA) Episode 88, Dr. Peter Attia and co-host Nick Stenson explore why the liver acts as the central hub of systemic metabolism and the "canary in the coal mine" for overall metabolic health.
• Fatty liver disease is estimated to affect more than 38% of the global adult population, yet the leading cause of death in patients with liver disease is cardiovascular disease rather than liver failure.
• The conversation traces the physiological progression of metabolic liver disease through four distinct stages—from initial metabolic stress and fat accumulation (steatosis) to inflammation (MASH) and irreversible scarring (fibrosis and cirrhosis).
• Attia breaks down the primary lifestyle and biological drivers of liver dysfunction, examining the roles of caloric surplus, visceral fat, skeletal muscle mass, dietary fructose, alcohol consumption, genetic variants, and menopause.
• Note on disclosures: Attia states that his podcast relies entirely on member subscriptions (peterattiamd.com/subscribe) rather than paid third-party ads, and notes that this content is for general informational purposes only and does not constitute medical practice.

Key Concepts

• The Two-Way Mirror of Liver and Systemic Health: The liver performs over 300 functions (per past guest Julia Wattacheril), which Attia groups into detoxification, immune defense via the portal vein, protein/hormone synthesis (including albumin, clotting factors, apoB, and IGF-1), and energy metabolism. Because it sits at the center of glucose, fat, protein, cholesterol, and alcohol metabolism, elevated circulating triglycerides, rising apoB/LDL cholesterol, or deteriorating glucose regulation directly reflect a stressed liver—and vice versa.
• Extreme Precision in Blood Glucose Homeostasis: A normal fasting blood glucose reading of 90 mg/dL equates to only about 4.5 grams (roughly 1 teaspoon) of glucose across the entire bloodstream. Even when consuming a single meal containing 90 grams of glucose (20 times the baseline bloodstream amount), a healthy liver and pancreas buffer this influx via glycogen storage and triglyceride conversion so that blood glucose rarely rises more than 1 teaspoon above baseline (Attia notes his own continuous glucose monitor rarely exceeded 160 mg/dL, a multi-day fast might only dip blood sugar to 50 mg/dL, and even someone with type 2 diabetes rarely exceeds 1.5 teaspoons at fasting).
• The Four Stages of Metabolic Liver Disease and Updated Nomenclature: Liver disease progresses through (1) metabolic stress, (2) steatosis (storing excess energy as fat), (3) steatohepatitis (inflammation and cellular self-injury), and (4) fibrosis (scar tissue replacing functional tissue, leading toward cirrhosis and elevated cancer risk). The first three stages are largely reversible, and very early fibrosis has varying degrees of biological reversibility, but advanced scarring that disrupts liver architecture is irreversible. Recent nomenclature updates replaced NAFLD (non-alcoholic fatty liver disease) with MASLD (metabolic dysfunction-associated steatotic liver disease—diagnosed when steatosis pairs with a cardiometabolic risk factor like hypertension, HbA1c-defined pre-diabetes/type 2 diabetes, dyslipidemia, or elevated BMI), and replaced NASH with MASH (metabolic dysfunction-associated steatohepatitis).
• Adipose Overflow and Selective Hepatic Insulin Resistance: During a consistent caloric surplus, the liver converts excess energy into triglycerides via de novo lipogenesis and exports them via apoB-containing particles (VLDLs and LDLs) to fat cells. When fat cells become overfilled, they accumulate a lipid intermediate called diacylglycerol (DAG), become insulin resistant, and leak free fatty acids back into circulation. As the liver absorbs these fatty acids, it develops tissue-specific insulin resistance (a concept Attia credits to past guest Ralph DeFronzo). In selective hepatic insulin resistance, insulin's signal telling the liver to stop releasing glucose fails, while its signal driving fat production remains active. As the pancreas pumps out more insulin to combat high blood sugar, hepatic fat production outpaces VLDL/LDL export, causing steatosis. When fat-overloaded hepatocytes die, they trigger an immune-driven inflammatory pathway that further disables insulin signaling in a feed-forward loop (MASH).
• The Anatomical Danger of Visceral Fat vs. Subcutaneous Fat: Unlike subcutaneous fat, which releases fatty acids into general systemic circulation, visceral fat (surrounding abdominal organs) is more prone to releasing fatty acids at baseline and drains directly into the portal vein straight to the liver. In a CT-scan cohort study, visceral fat predicted steatosis independent of BMI and liver enzymes, with patients holding >200 cm² of visceral fat showing a 7.5-fold greater increase in liver steatosis than those below 100 cm². Furthermore, NHANES data show that among people with diagnosed MASLD, those in the top quartile of visceral adiposity had nearly 3.5 times the all-cause mortality of those in the lowest quartile.
• Skeletal Muscle as the Primary Glucose Sink: Roughly 75% of the body's total glycogen storage capacity resides in skeletal muscle, while only about 25% is in the liver. Individuals with low muscle mass and a normal BMI ("skinny fat" or sarcopenic obesity) lack this muscular buffer, forcing the liver to shoulder a heavier glucose burden.
• Fructose Mechanics vs. Isocaloric Reality: In a 7-week randomized trial of 94 healthy men at stable weight, moderate consumption of fructose- or sucrose-sweetened (50/50 fructose/glucose) beverages roughly doubled baseline hepatic de novo lipogenesis compared to glucose alone. However, in controlled feeding studies measuring actual liver fat accumulation (steatosis), excess total calories are the dominant driver: swapping fructose isocalorically for other carbohydrates barely changes liver fat. Fructose is strongly linked to MASLD in cohort data primarily because liquid sugars (like soda and high-fructose corn syrup beverages) fail to induce satiety and easily drive a caloric surplus.
• The Synergistic Lethality of Alcohol and Steatosis (MetALD): The overlap of metabolic dysfunction and alcohol use is now classified as MetALD (metabolic and alcohol-associated liver disease). In an NHANES cohort study of patients with cardiometabolic risk factors, steatosis alone did not increase all-cause mortality, whereas combining steatosis with self-reported intake of roughly 40 to 60 grams of ethanol per day for men (3 to 4 standard drinks, and slightly less for women—though Attia notes self-reporting may underestimate true intake) resulted in hazard ratios of 1.4 for all-cause mortality (+40%), 2.35 for cancer mortality (+135%), and 15 for liver-specific mortality (+1,400%). Attia also notes he was previously surprised by liver transplant data showing how many transplants stem from non-alcoholic versus alcoholic causes, though he hedges that he does not recall the exact latest numbers.
• Genetic, Ancestral, and Hormonal Modifiers: Carrying two copies of a specific PNPLA3 gene variant doubles the risk of liver fat accumulation and raises inflammation and fibrosis risk independent of standard metabolic factors, whereas a loss-of-function variant in HSD17B13 is protective and may partially offset PNPLA3 risk. At a population level, the PNPLA3 risk variant is much more common in individuals of Hispanic ancestry and much less common in those of African ancestry—though Attia strongly cautions that population genetics do not dictate individual destiny. Additionally, individuals of Asian ancestry often develop visceral adiposity and metabolic liver risk at lower BMIs due to lower subcutaneous fat storage capacity, and postmenopausal women lose the protective effect of estrogen against visceral and hepatic fat, leading to more frequent and aggressive fatty liver progression.

Quotes

• At 1:38 - "The leading cause of death in people with liver disease isn't liver failure, it's cardiovascular disease, because a liver under metabolic stress is overproducing apoB-containing particles and amplifying the insulin resistance that drives atherosclerosis throughout the body." - Attia explaining why hepatic metabolic stress is a primary driver of systemic cardiovascular risk.
• At 5:55 - "Let's say that number you get back says 90 milligrams per deciliter, that was your blood glucose that morning when you showed up at the lab. If that's the case, your entire bloodstream in that moment contained only about four and a half grams of glucose. That's roughly a teaspoon, not a tablespoon, just a teaspoon." - Attia illustrating how tightly the liver and pancreas regulate circulating blood sugar.
• At 12:29 - "Insulin normally tells the liver to do two things: stop releasing glucose into the bloodstream and stop making new fat cells. Why? Because if insulin is high, you've just been fed, and if you're fed, you don't need to be putting glucose into the bloodstream or making new fat. But as insulin resistance develops, the first signal fails before the second, so the liver continues releasing glucose even when blood sugar is already high, while the pancreas responds by making more insulin, which still drives fat production." - Attia detailing the mechanism of selective hepatic insulin resistance and why it traps fat in the liver.
• At 21:40 - "The single most striking figure comes from a large seven-year Korean cohort. People who gained the most muscle over the study resolved their MASLD at more than four times the rate of those who gained the least muscle." - Attia highlighting the power of building skeletal muscle to resolve fatty liver disease.
• At 23:40 - "But on the harder outcome, actual steatosis, controlled feeding studies show the dominant driver is excess calories and not fructose itself. So if you swap fructose isocalorically for other carbohydrates, liver fat barely moves." - Attia clarifying that total caloric surplus, rather than fructose in isolation, is what causes fat accumulation in the liver.
• At 27:19 - "Steatosis plus what they described as moderate and I might call moderate-plus alcohol consumption produced hazard ratios of 1.4 for all-cause mortality, 2.35 for cancer mortality, and a whopping 15—please check that number again, yes, 15x—for liver-specific mortality versus people with no steatotic liver disease." - Attia sharing NHANES data on the compounding danger of drinking alcohol when fatty liver and cardiometabolic risk factors are already present.

Takeaways

• Build skeletal muscle through resistance training to offload the liver: Because skeletal muscle accounts for roughly 75% of the body's glycogen storage capacity, increasing muscle mass expands your glucose sink and reduces the metabolic burden on the liver—an intervention associated with resolving MASLD at more than four times the rate of minimal muscle gain in longitudinal research.
• Eliminate caloric surpluses by cutting out liquid sugars: To prevent or reverse the first three stages of metabolic liver disease, focus on overall energy balance rather than obsessing over isocaloric carbohydrate swaps, starting by removing sugar-sweetened beverages that bypass satiety signals and upregulate hepatic fat synthesis.
• Strictly limit alcohol—especially if you have metabolic risk factors—and avoid binge drinking: If you have steatosis or cardiometabolic dysfunction, avoid heavy daily drinking to prevent the massive spike in liver and cancer mortality seen in MetALD; if you do drink, pace consumption below roughly 1 drink per hour so the liver can clear toxic acetaldehyde, as Attia notes mechanistically (while hedging that direct human RCT data don't exist) that 7 drinks in one night is likely far more damaging to the liver than 1 drink per night over 7 nights.